Study of SD-101 for epidermolysis bullosa in children
Part of Genetic & congenital, Skin clinical trials.
This trial tests a new medicine called SD-101 for children with epidermolysis bullosa (EB), a condition that causes fragile skin and blistering. It aims to see if SD-101 can help heal wounds and improve quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child is between 28 days and 12 years old.
- Your child has been diagnosed with simplex, recessive dystrophic, or intermediate junctional EB.
- Your child has at least one wound that is 10 to 50 square centimeters (about the size of a credit card to a small hand) and has been present for at least 21 days.
- The total skin affected by wounds is at least 5% of their body surface area.
- Your child has not used certain treatments (like steroids, antibiotics, or other investigational drugs) within the past month.
- Your child does not have a current or past cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is a safety follow-up for people who already completed the SD-007 trial. It gives everyone SD-101, an experimental treatment for epidermolysis bullosa, to see how well it works over a longer period.
This trial tests a gel called TCP-25 on wounds caused by a specific type of epidermolysis bullosa (DEB or JEB). It aims to see if the gel can help heal wounds and improve comfort.
This trial tests a skin cell treatment called pz-cel (made from your own cells) for people with a severe skin condition called dystrophic epidermolysis bullosa (DEB). It aims to help heal wounds by applying specially grown skin sheets.
This trial tests a drug called efgartigimod (VYVGART) to see if it can lower harmful antibodies in people with certain blistering skin diseases—dystrophic epidermolysis bullosa (DEB) and epidermolysis bullosa acquisita (EBA). If you have these antibodies, this treatment might help reduce blistering.
This study tests an experimental eye drop (KB803) to see if it can reduce painful scrapes on the surface of the eye in people with dystrophic epidermolysis bullosa. You would be randomly assigned to receive either the study drops or a placebo (an inactive drop) for several months.
This early-stage study tests stem cell–derived “extra-cellular vesicles” (small natural cell packages) to help heal painful skin wounds in people with dystrophic epidermolysis bullosa (DEB). If you have suitable, untreated wounds and meet the safety requirements, you may be able to join and help researchers learn whether this treatment is beneficial.
Hear when a new Epidermolysis Bullosa (EB) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.